The Food and Drug Administration’s public calendar shows Commissioner Martin A. Makary scheduled for CES in Las Vegas, reflecting how central “digital health” has become to the agency’s public-facing agenda.
CES has increasingly featured health-focused technologies—ranging from wearables and at-home diagnostics to software-driven care tools—bringing regulators into closer contact with consumer tech and medical-device ecosystems.
The listing highlights a talk described as focusing on a “new era of digital health,” a theme that points to ongoing regulatory attention on how data, devices, and software change clinical care and oversight.
For companies, visibility of FDA participation at CES is often read as a signal that regulatory expectations and innovation timelines are tightening together.